Xenon to Report Q2 2024 Financial Results on August 8, 2024
We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 24% Below Their Intrinsic Value Estimate
Is Xenon Pharmaceuticals Inc. (XENE) One of the Best Healthcare Stocks Under $50?
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $55
Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 25% Above Its Share Price
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Express News | Xenon Pharmaceuticals Presents Phase 2 X-NOVA Clinical Trial Data Of Azetukalner in Major Depressive Disorder At ASCP 2024 Annual Meeting
Express News | Xenon Pharmaceuticals Presents Data From Phase 2 X-Nova Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
Hedge Funds Are Racking Up Shares of This Healthcare Stock
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Express News | Xenon Pharmaceuticals Inc : JP Morgan Raises Target Price to $63 From $60
Xenon Pharmaceuticals Insiders Sell US$4.5m Of Stock, Possibly Signalling Caution
Xenon Pharmaceuticals Price Target Maintained With a $62.00/Share by Needham
Xenon Pharmaceuticals Is Maintained at Buy by Citigroup
Express News | Citigroup Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60
Xenon Pharmaceuticals: A Strong Buy on Clinical Progress and Robust Financials
Xenon Pharmaceuticals Inc (XENE) Reports Increased Losses in Q1 2024, Despite Advancements in ...
Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush
Xenon Pharmaceuticals Analyst Ratings